Gan & Lee Pharmaceuticals. (SHA:603087)

Market Cap	32.61B
Revenue (ttm)	3.47B
Net Income (ttm)	830.58M
Shares Out	598.96M
EPS (ttm)	1.41
PE Ratio	38.55
Forward PE	31.84
Dividend	1.50 (2.77%)
Ex-Dividend Date	Jun 11, 2025

Volume	6,364,291
Average Volume	14,948,473
Open	53.51
Previous Close	53.49
Day's Range	53.21 - 53.96
52-Week Range	37.63 - 59.16
Beta	1.61
RSI	48.80
Earnings Date	Aug 29, 2025

About SHA:603087

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. The company’s products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro and lispro mix 75/25 injection; Prandilin 25, an insulin lispro injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, an insulin injection. It also offers GanleePen, an insulin injection device; ...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1998
• Employees: 5,245
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603087

Financial Performance

In 2024, SHA:603087's revenue was 3.05 billion, an increase of 16.77% compared to the previous year's 2.61 billion. Earnings were 614.66 million, an increase of 80.75%.